Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · IEX Real-Time Price · USD
0.525
-0.068 (-11.48%)
At close: Jul 19, 2024, 4:00 PM
0.537
+0.012 (2.21%)
Pre-market: Jul 22, 2024, 7:44 AM EDT
Company Description
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company.
The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma.
It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.
The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited
Country | Australia |
Founded | 1994 |
IPO Date | Jan 6, 1999 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Dr. John Edwin Friend II, M.D. |
Contact Details
Address: 120 Broadway, 32nd Floor New York, New York 10271 United States | |
Phone | 212 238-3128 |
Website | kaziatherapeutics.com |
Stock Details
Ticker Symbol | KZIA |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | AUD |
CIK Code | 0001055886 |
CUSIP Number | 48669G105 |
ISIN Number | US48669G1058 |
SIC Code | 8880 |
Key Executives
Name | Position |
---|---|
Dr. John Edwin Friend II, M.D. | Chief Executive Officer, MD and Director |
Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, Vice President of Finance and Administration and Principal Financial Officer |
Anna Sandham | Company Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 21, 2017 | 424B3 | Prospectus |
Nov 17, 2017 | 424B3 | Prospectus |
Jul 11, 2017 | 424B3 | Prospectus |
Jun 6, 2016 | F-6 POS | Post-effective amendments for immediately effective filing |